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ABSTRACT
Introduction: In clinical practice, it is difficult to
distinguish between patients with refractory asthma from
those with poorly controlled asthma, where symptoms
persist due to poor adherence, inadequate inhaler
technique or comorbid diseases. We designed an audio
recording device which, when attached to an inhaler,
objectively identifies the time and technique of inhaler
use, thereby assessing both aspects of adherence. This
study will test the hypothesis that feedback on these two
aspects of adherence when passed on to patients
improves adherence and helps clinicians distinguish
refractory from difficult-to-control asthma.
Methods: This is a single, blind, prospective,
randomised, clinical trial performed at 5 research
centres. Patients with partially controlled or uncontrolled
severe asthma who have also had at least one severe
asthma exacerbation in the prior year are eligible to
participate. The effect of two types of nurse-delivered
education interventions to promote adherence and
inhaler technique will be assessed. The active group
will receive feedback on their inhaler technique and
adherence from the new device over a 3-month period.
The control group will also receive training in inhaler
technique and strategies to promote adherence, but no
feedback from the device. The primary outcome is the
difference in actual adherence, a measure that
incorporates time and technique of inhaler use between
groups at the end of the third month. Secondary
outcomes include the number of patients who remain
refractory despite good adherence, and differences in
the components of adherence after the intervention.
Data will be analysed on an intention-to-treat and a
per-protocol basis. The sample size is 220 subjects
(110 in each group), and loss to follow-up is estimated
at 10% which will allow results to show a 10%
difference (0.8 power) in adherence between group
means with a type I error probability of 0.05.
Trial registration number: NCT01529697; Pre-results.
INTRODUCTION
Approximately 10% of patients with asthma
remain poorly controlled with persisting
symptoms and severe exacerbations despite
use of combination therapy with long-acting
β agonists and inhaled corticosteroids.1 This
poor control may be due to medication
refractory asthma or due to difﬁcult-
to-manage asthma from issues such as poor
inhaler technique, poor adherence or coex-
isting comorbid disease.1–3 In practice, distin-
guishing refractory from difﬁcult-to-manage
asthma is difﬁcult. For example, adherence
to medications, a particular problem in
patients with severe asthma, is difﬁcult to
detect since self-report is unreliable,4 and
pharmacy reﬁll records only identify if the
individual has collected a prescription. Some
patients may demonstrate a reasonable
inhaler technique when directly observed,
but may be careless in their inhaler use on a
day-to-day basis.5 Hence, without objective
longitudinal information on inhaler adher-
ence and technique it is challenging to dis-
tinguish a patient with refractory asthma
from one who has difﬁcult-to-manage
asthma.6
We developed a device, INhaler Compliance
Assessment (INCA), which makes a digital
audio recording of an inhaler being
used.5 7–13 Analysis of the audio recordings
by automated signal processing techniques,
provides an objective assessment of both the
time and the technique of inhaler use.
Validation of the device and the audio
recordings have been previously pre-
sented.5 7–13 We hypothesised that this
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information could be used both as part of an educa-
tional consultation for patients and for clinicians to
help distinguish refractory from difﬁcult-to-manage
asthma.
The objective of this study is to assess if inhaler use
obtained from the INCA device on time and technique
of use leads to better inhaler adherence and better clin-
ical information than current best practice.
METHODS
We describe the protocol of a randomised, single blind,
nurse-delivered education study. The study will comprise
patients with severe asthma attending specialist hospital
asthma clinics, who remain uncontrolled and have
experienced at least one recent severe asthma exacerba-
tion. Basing on information obtained directly from the
INCA acoustic recording device, one group (the active
arm) will discuss patterns of adherence and training on
technique of inhaler use. The second group (the
control arm) will be given generalised strategies to
improve adherence, while technique errors will be cor-
rected using checklists.14 Adherence will be assessed
objectively in all participants. Global outcomes will be
quantiﬁed using the clinical, lung function, adherence
and exacerbation data collected during the observation
period.
Sponsorship
This is a researcher-initiated study, funded by the Health
Research Board of Ireland (Pro/2011/57), and hosted
within the Dublin Centre for Clinical Research clinical
trials centres. The study sponsor, Royal College of
Surgeons, is an independent medical university. The
trial was approved by the Beaumont Hospital’s Ethics
committees. The trial is registered as NCT01529697 on
Clinicaltrials.gov and a detailed statistical plan has been
approved by an independent statistical team. The INCA
device was manufactured and supplied by Vitalograph,
Ennis, Ireland, and GlaxoSmithKline provided the sal-
meterol/ﬂuticasone Diskus inhaler for this study.
Setting
This is a prospective, multicentre, single blind, rando-
mised controlled trial of two nurse-delivered strategies to
optimise inhaler technique and adherence of patients
with stage 3 to 5 asthma. The study is being conducted
at the Clinical Research Centres of ﬁve university hospi-
tals within the republic of Ireland (4 in Dublin County,
1 in Cork County). At each centre between one and
three nurses have been trained to provide either inter-
vention. The lead clinical nurse was educated by the
principal investigator and a respiratory nurse specialist.
All other nurses were educated by our lead clinical
nurse in a teach-to-goal method with demonstration.
The study period is from 2011 with ongoing
recruitment.
Participants (n=220)
Prior to study recruitment, an asthma diagnosis is made
using a clinician diagnosis supported by one or more of
the following: obstructive spirometry with a minimum of
10% reversibility, either spontaneously over time or with
inhaled β agonist, or with a minimum 15% peak ﬂow
variability over time or through a positive bronchial
provocation challenge.
Inclusion criteria
Patients already prescribed therapy equivalent to step 3
or higher on the Asthma Management Guidelines (1)
for at least 3 months, and who had at least one exacerba-
tion treated with systemic glucocorticoids in the prior
year, and who are either uncontrolled or partially con-
trolled by Global Initiative for Asthma (GINA) guide-
lines are eligible for inclusion.1 Patients must also be
18 years or older in age.
Exclusion criteria
Patients who are controlled, as deﬁned by the GINA cri-
teria1 on their current therapy are excluded. Additional
exclusion criteria are those who are unwilling to partici-
pate in a clinical study, or prior hypersensitivity to
salmeterol/ﬂuticasone. There are no other exclusion
criteria.
Study design
The study ﬂow is indicated in table 1.
Patients identiﬁed at specialist asthma clinics who
meet the inclusion and not the exclusion criteria are
invited to participate in the study. Once consented, each
study visit is performed by a registered nurse.
The dose of inhaled corticosteroid and Long Acting
Beta-Agonist (LABA) is not changed at recruitment and
during the study procedure, as the main aim of the study
is to improve adherence to current asthma treatment.
The audio recording technology has not yet been
established for the turbohaler or the pressurised
metered dose inhaler (pMDI), hence, for those partici-
pants who are currently prescribed formoterol/budeso-
nide/beclomethasone at recruitment, their therapy is
changed to an equivalent dose of salmeterol/ﬂuticasone
delivered via the Diskus device. This change is made by
the physician looking after the patient in the outpatient
clinic. Following this, the patient is then referred to the
study. The patient may still refuse to enter the study. All
other aspects of regular patient care are continued.
At the initial visit, the participant’s age, sex, height,
weight, duration of asthma, smoking history, number of
courses of steroids in the prior year are recorded (self-
reported by the participant). The dose of salmeterol/
ﬂuticasone and duration of taking this dose, use and
dose of other inhaled therapy including short-acting β
agonists, long acting muscarinic antagonist, nasal steroid
and antihistamines are recorded. The nurse records the
peak expiratory ﬂow rate (PEFR) and an Inhaler
Proﬁciency checklist Score (IPS; see online
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supplementary appendix 1), a 10-point checklist score.
The Asthma Control Test (ACT) score and Asthma
Quality of Life Questionnaire (AQLQ)15 are completed
by the participant. Serum total and speciﬁc immuno-
globulin E levels and peripheral blood eosinophil levels,
prior spirometry and bronchial provocation test are
recorded from the clinical notes.
The participants receive a salmeterol/ﬂuticasone
Diskus inhaler with an INCA device attached, and they
are asked to use the inhaler twice per day and to take
reliever salbutamol, as required, for breakthrough symp-
toms. All participants are informed at recruitment that
the device would provide information on how and when
they use their inhaler. Participants are asked to record
their peak expiratory ﬂow with an electronic monitor
(ASMA-1, Vitalograph, Ennis, Ireland) twice daily.
Visits are scheduled 4, 8 and 12 weeks later, sum-
marised in ﬁgure 1. At these visits, the participants
return their inhaler and electronic peak ﬂow monitor.
Additionally, at each of these visits the ACT, AQLQ,
PEFR as well as any exacerbations and changes in medi-
cations, including new medications are recorded. Owing
to an omission in the original study protocol, where
ACT was not a measured variable, it was not recorded on
the ﬁrst 60 participants. The training, as per allocation,
is then given. Details of the clinical visits are included in
the clinical training manual, online supplementary
appendix 2.
Interventions
Control group: behavioural intervention and inhaler training
The key points of each of the visit consultations
includes: participant-identiﬁed goals for outcomes,
exploration of barriers to achieving goals, explanation of
the purpose of asthma treatment and provision of an
asthma management plan for exacerbations. A checklist
Table 1 Details of study data collection
Study procedure Visit 1 Visit 2 Visit 3 Visit 4
Informed consent X
Demographics X
Medical history X
Inclusion and
exclusion criteria
X
Current medications X
Physical examination X X
X X X X
AQLQ X X X X
ACT X X X X
Randomisation X
Dispense adapted
Seretide inhaler
X X X
Dispense electronic
PEFR monitor
X X X
Download device
readings active only
X X X
Inhaler use education X X X X
Adverse events
recorded
X X X
Concomitant
medications recorded
X X X
The active group receive a copy of device readings and active
feedback about adherence and inhaler technique,
visit 1: screening visit: at time of enrolment (week 0); visit 2: at
end of month 1 (week 4); visit 3: at end of month 2 (week 8); visit
4: final visit at the end of month 3 (week 12).
AQLQ, Asthma Quality of Life Questionnaire; ACT, Asthma Control
Test; PEFR, peak expiratory flow rate.
Figure 1 The study participants are patients with a diagnosis of asthma attending a severe asthma clinic who remain
uncontrolled or partially controlled and have experienced at least one severe exacerbation of asthma in the prior year. With no
medication change, adherence and inhaler technique are re-enforced over the 12-week monitoring period (INCA, INhaler
Compliance Assessment).
Sulaiman I, et al. BMJ Open 2016;6:e009350. doi:10.1136/bmjopen-2015-009350 3
Open Access
group.bmj.com on January 7, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
is used to review and correct errors in inhaler technique
(IPS). To promote adherence during the education,
emphasis is given on the individual developing a habit
in time of use of the inhaler. Four, 8 and 12 weeks later
the participants return their inhaler and receive an iden-
tical structured consultation as at the ﬁrst meeting.
Participants and nursing staff are unaware of data from
the INCA device in the control arm. A video and
manual describing the exact steps of usual care is shown
as https://www.youtube.com/watch?v=PlTkhVuogaI.
Active group: feedback using recordings from the
INCA device
The content of the ﬁrst visit was the same as for the
control group. At 4, 8 and 12 weeks later, the partici-
pants together with the nurse review the information
recorded on the INCA device and electronic PEFR
(ePEFR), in the form of a graph, see ﬁgure 2 for an
example of graphs produced by the INCA device. This
graph leads to a consultation that focuses on the time of
use, patterns of inhaler use, attempting to identify bar-
riers to good adherence, development of habit of use as
well as remediation of errors in inhaler use, as identiﬁed
by the analysis of the data.
Data collection
INCA device
The original INCA device was designed at the
Department of Bioengineering, Trinity College Dublin,
Ireland and Conformité Européenne (CE) marked and
manufactured by Vitalograph, Ennis, Ireland.
Analysis of the audio data
Analysis of the digital recordings is performed as previ-
ously described.5 The ﬁles are uploaded to a server and
analysed using signal processing methods. For patients
in the active arm, these audio recordings are uploaded
during the visit by the nurse and feedback is given to
Figure 2 A screen shot of the
data presented to the patient for
discussion of their adherence to
the salmeterol/fluticasone Diskus
inhaler over the prior month. In
this example, the patient has
good time of use, in particular in
the evening, suggesting they are
developing a regular habit of use.
However, they show intermittent
errors in inhaler technique. In this
example, they used the inhaler
incorrectly on almost half of all
occasions in which the inhaler
was used.
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the patient based on an automated analysis of the audio
ﬁles. The sensitivity and speciﬁcity details have been
published.7
At a later date, two independent raters over-read all
ﬁles from all patients. Their agreed, combined analysis
will be used in the calculation of the actual adherence.
These raters are unaware of either the patient allocation
or any of the patient clinical outcomes and are not
involved in any aspect of the patient care during the
trial. Critical inhaler errors including whether the drug
was primed, whether the patient exhaled after priming
but before inhalation, whether an adequate ﬂow rate
was achieved, the exact ﬂow rate, whether there were
multiple inhalations indicating inadequate breath-holds
and correct sequence of events/timing of events were
performed. Non-critical errors such as not holding the
device vertically (as described by the manufacturer)
were not recorded. The sensitivity and agreement within
the two raters and between the raters and the algorithm
have been published.9 Any disagreements within raters
were reviewed by a third rater who made the ﬁnal deci-
sion on the audio ﬁle.
Electronic peak expiratory flow rate
Participants receive an ePEFR device at each visit, which
are then collected at the subsequent visit. For partici-
pants in the active arm, data from these devices are
downloaded during the visit and information on PEFR,
in conjunction with adherence data from the INCA
device, are feedback to the participant.
Objectives
The objective of this study is to assess if feedback
obtained from the INCA device on adherence and tech-
nique errors yields better adherence and better clinical
information than best practice.
Primary outcome
The actual inhaler adherence, expressed as cumulative
drug exposure, is calculated by combining the time of
use along with the interval between doses (correct time
is twice a day, in a period not <6 h between the last dose
and the subsequent doses, or at a time >18 h apart from
the previous dose) and incorporating, by audio analysis,
if the inhaler was used correctly (ie, no evidence of crit-
ical technique errors aforementioned). The rate of
actual adherence for the last month of the intervention
will be compared between the active and control
patients.
Secondary outcome analysis will include
Clinical outcomes, PEFR, ACT, AQLQ, reliever use and
exacerbations between active and control arms at the
end of the study will be compared. A composite score of
these values, the global clinical outcome proﬁle, see
table 2 comprising the observed adherence, peak ﬂow
data, asthma control, quality of life and reliever use, as
well as exacerbations over the study period will be calcu-
lated. Exacerbations is deﬁned as an increase in symp-
toms (ie, shortness of breath, wheeze, cough) requiring
a course of systemic glucocorticoids. Healthcare utilisa-
tion (ie, unscheduled general practitioner visits, hospi-
talisation and emergency department visits) will also be
compared between active and control arms.
Comparison of the proportion of patients in each
group who achieved full adherence at the end of the
study (≥80%), as well as changes in patterns of adher-
ence in the two groups, the number progressing to good
actual technique will be assessed. A comparison of the
morning and evening habits of inhaler use, error rates,
overdose rates, interval and attempted rates of adher-
ence in the two groups at the end of the study will be
compared. The factors associated with improving adher-
ence will be described.
The relationship between adherence and asthma
control, asthma quality of life and PEFR will be assessed
by comparing the proportion of patients who are GINA
2011, ACT controlled and no longer require regular β
agonist. The ACT, PEFR rate, AQLQ and reliever use
between the two groups will also be compared.
The κ score between raters and a sensitivity analysis of
the algorithm will be calculated.
Sample size calculation
The usual rate of adherence to inhalers is reported to
be calculated from the dose counter, and is expressed as
Table 2 Clinical decision tool
Non-adherence Refractory asthma Controlled asthma Comorbidity
Actual adherence >80% No Yes Yes or no Yes
PEFR >80 of area under the curve Yes or no No Yes Yes
AQLQ >5 and ACT >19 Yes or no No Yes No
Exacerbations Yes or no Yes or no No Yes or no
The outcome decision tool, at the end of the study the cumulative information on actual adherence. PEFR rate, calculated as the AUC within
80% of normal predicted. ACT and AQLQ considered to be optimal, and exacerbations will be used to describe one of four possible
outcomes. Sufficiently non-adherent as the likely reason for failure to progress, asthma that is refractory because despite optimal adherence,
both symptoms and lung function and exacerbations occur. Controlled asthma, patients who are no longer impaired nor have exacerbations,
and a group of patients who have good adherence and lung function but who continue to have symptoms, therefore suggesting that a
significant comorbidity is the likely driver for the ongoing symptoms.
ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; PEFR, peak expiratory flow rate.
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an average adherence. Most studies in trials of patients
with inhalers report adherence of >0.8. Therefore, we
anticipate that there is going to be high adherence in
the setting of a clinical trial. However, we also expect
that there will be a number of patients with poor inhaler
technique which will lead to a lower actual adherence.
We shall assume that when this is accounted for then
the actual adherence is 0.15 lower, that is, 0.65 adher-
ence at the end of the ﬁrst month. Our preliminary data
in primary care and on the wards indicates an SD of
adherence is 0.25.5 The primary end point is the rate of
adherence at the end of the study period, that is, during
the last visit at month 3 between active and control
groups. We expect the adherence to improve over the
study period in the control group, as they are repeatedly
educated in inhaler use by 0.05, and we expect the
active group to get closer to the physician-reported ideal
rate of 0.8, that is, a 0.15 improvement in actual adher-
ence. Hence, with a power of 0.8 at the 0.05 signiﬁcance
level, with a 0.1 difference in the actual adherence rate,
then a sample size of 100 in each limb is required. We
expect a 10% dropout; hence the target recruitment
sample size is 220 in total.
Randomisation and allocation
Randomisation will use a stratiﬁed-by-site random block
design, with blocks varying in size of 8–12. Allocation
ratio is 1:1 with a central computer-generated random-
isation. This is a single blind study, the nurse may deliver
either intervention and is not blinded to the allocation.
The participants are aware which group they are allo-
cated to and aware that data on adherence is being col-
lected for analysis. Patients in the control arm will be
blinded to their adherence data from the INCA device.
Statistical methods
Data analysis
Data will be analysed on an intention-to-treat and a per-
protocol basis. Data will be presented as means with SDs,
and Student t test will be used to compare differences in
mean adherence rates between the groups. Signiﬁcance
will be set at the 5% level. Stratiﬁcation of patients by
new versus previous use with respect to use of the Diskus
device (ie, if patient’s are using the Diskus device for
the ﬁrst time, or if they have previously used the device),
stratiﬁcation based on severity of disease according to
GINA guidelines.
DISCUSSION
Most management guidelines suggest that for poorly
controlled asthma patients that before changing therapy,
issues with adherence and inhaler technique need to
be addressed.1–3 However, this is difﬁcult to achieve in
clinical practice. The aim of this study is to see if a
nurse-delivered educational intervention with repeated
education and monitored adherence can improve both
aspects of adherence, the time and the technique of
inhaler use. We will record when and how well an indi-
vidual has used their inhaler over time with a device that
makes a digital audio recording of an individual using
their inhaler. Analysis of the recorded time of use, the
interval between use and technique of use provides a
measure termed actual adherence. The study’s primary
outcome will be a comparison of the actual adherence
between the two groups at the end of the third month
of participation in the study.
It is expected that over the study period some patients
will become fully controlled while others will remain
poorly controlled despite being fully adherent over the
study period, and others may remain uncontrolled and
also poorly adherent. This information may help with
clinical decision-making for individual patients, for
example, by helping decide who should have their
therapy increased, their inhaler device changed or
further interventions to promote adherence such as
motivational interviewing. Hence, by combining clinical
outcomes with the longitudinally collected adherence,
asthma control and PEFR data, the composite outcome
may assist a clinician in identifying the cause of
difﬁcult-to-manage asthma and increase the clinical con-
ﬁdence that the patient has refractory asthma.
This study has several novel features; this is the ﬁrst
study to use a technology that objectively assesses adher-
ence to inhalers both in terms of technique of use as
well as time of use. This technology involves not simply
the device but also the automated algorithms, the feed-
back tools and the content of the feedback delivered by
the nurse during the consultation.
It could be argued that the results of this clinical
research study, performed in a research setting, will lead
to greatly improved adherence, which is not reﬂective of
clinical practice. Additionally, both control and active
patients will be reviewed on a monthly basis for
3 months. This approach itself will more than likely also
lead to an increase in adherence in the active and
control group and may not fully reﬂect ‘usual care’. To
add to this, patients in both the active and control arms
are aware that their inhaler use is being ‘monitored’,
and this may lead to increased inhaler adherence. The
authors see no alternative way of performing the study,
as practical challenges in a more real-world setting may
lead to a signiﬁcant loss of patient follow-up, and hence,
less precise information. The beneﬁts of regular visits
and PEFR measurements outweigh the disadvantages.
Another limitation of the study is that it has a limited
follow-up time frame, hence, the long-term effect on
clinical outcomes and persistence of the observed bene-
ﬁts will not be established.
In regard to safety, patients enrolled in this study have
to be uncontrolled or partially controlled by GINA
guidelines. However, for the duration of the study their
regular medical treatment of their asthma will not be
changed (ie, their ICS/LABA dose will remain
unchanged). The rationale behind this is to see the
effect 3 months of adherence training would have on
6 Sulaiman I, et al. BMJ Open 2016;6:e009350. doi:10.1136/bmjopen-2015-009350
Open Access
group.bmj.com on January 7, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
asthma control, potentially reducing the need to
increase patient medication (step-up), and possibly
allowing physicians to reduce asthma treatment (step-
down). Patients can withdraw at any time during the
study without any impact on their clinical care.
Additionally, if the clinician feels there is a clinical indi-
cation, patients can be removed from the study in the
patient’s best interest.
In summary, this study proposes to assess the impact of a
series of consecutive educational visits on adherence and
inhaler use by patients with severe asthma. In addition, by
combining objective measurement of lung function, clin-
ical outcomes and objectively assessed adherence, this may
also provide clinicians greater precision in decision-
making for the future care of this group of patients.
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